palbociclib
pfizer,medsir
['palbociclib', 'bcsm', 'palbo', 'palmira']
continuation of palbociclib after progression in 1st-line: palmira median follow-up 13.2 mo
60% visceral disease pfs 4.9 vs 3.6 mo, hr 0.84 (ci 0.66-1.07)
no difference in os
no subgroup with significant benefit antonio llombart-cussac #asco23 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.